Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Classificação em ações #33640
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Preço da ação
$0.03702159
Última sincronização: 2024-01-29
Valor de mercado
$7.21M
Variação (1 dia)
-3.08%
Variação (1 ano)
0.00%
País
AU
Negociar Antisense Therapeutics Limited (ANP)

Categoria

Rácio P/B de Antisense Therapeutics Limited (ANP)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Antisense Therapeutics Limited, o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Antisense Therapeutics Limited de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes